comparemela.com
Home
Live Updates
Urovant Sciences, Inc.: Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management : comparemela.com
Urovant Sciences, Inc.: Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management
Review article in a peer-reviewed journal examines studies of GEMTESA published in the past 3 years Data support GEMTESA's role as an effective treatment option for overactive bladder (OAB)
Related Keywords
China ,
Japan ,
United States ,
Americans ,
Sumitomo Dainippon Pharma ,
Sumitovant Biopharma ,
Maya Frutiger ,
Alana Darden Powell ,
Cornelia Haag Molkenteller ,
Jeffrey Frankel ,
Linkedin ,
Twitter ,
Aboutsumitovant Biopharma Ltd ,
Dainippon Pharmaceutical Co Ltd ,
Seattle Urology Research Center ,
Corporate Communications ,
Sumitomo Dainippon Pharma Co Ltd ,
Urovant Sciences ,
Sumitomo Pharmaceuticals Co Ltd ,
Sumitovant Biopharma Ltd ,
Clinical Risk Management ,
Seattle Urology Research ,
Chief Medical Officer ,
Product Information ,
Dainippon Pharma ,
Darden Powell ,
Urovant ,
Ciences ,
Nnounces ,
Publication ,
Review ,
Efficacy ,
Safety ,
Data ,
Gemtesa ,
Vibegron ,
Overactive ,
Ladder ,
Patients ,
Journal ,
Herapeutics ,
Linical ,
Risk ,
Management ,
comparemela.com © 2020. All Rights Reserved.